Home Cart 0 Sign in  

[ CAS No. 1092351-67-1 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
Chemical Structure| 1092351-67-1
Chemical Structure| 1092351-67-1
Structure of 1092351-67-1 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Quality Control of [ 1092351-67-1 ]

Related Doc. of [ 1092351-67-1 ]

Alternatived Products of [ 1092351-67-1 ]

Product Details of [ 1092351-67-1 ]

CAS No. :1092351-67-1 MDL No. :MFCD12196869
Formula : C16H16N6O Boiling Point : -
Linear Structure Formula :- InChI Key :MFAQYJIYDMLAIM-UHFFFAOYSA-N
M.W : 308.34 Pubchem ID :135565635
Synonyms :
PP242
Chemical Name :2-(4-Amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-1H-indol-5-ol

Calculated chemistry of [ 1092351-67-1 ]

Physicochemical Properties

Num. heavy atoms : 23
Num. arom. heavy atoms : 18
Fraction Csp3 : 0.19
Num. rotatable bonds : 2
Num. H-bond acceptors : 4.0
Num. H-bond donors : 3.0
Molar Refractivity : 89.92
TPSA : 105.64 Ų

Pharmacokinetics

GI absorption : High
BBB permeant : No
P-gp substrate : Yes
CYP1A2 inhibitor : Yes
CYP2C19 inhibitor : No
CYP2C9 inhibitor : No
CYP2D6 inhibitor : No
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -6.75 cm/s

Lipophilicity

Log Po/w (iLOGP) : 1.89
Log Po/w (XLOGP3) : 2.01
Log Po/w (WLOGP) : 2.85
Log Po/w (MLOGP) : 1.42
Log Po/w (SILICOS-IT) : 1.75
Consensus Log Po/w : 1.98

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 0.0
Bioavailability Score : 0.55

Water Solubility

Log S (ESOL) : -3.47
Solubility : 0.106 mg/ml ; 0.000343 mol/l
Class : Soluble
Log S (Ali) : -3.86
Solubility : 0.043 mg/ml ; 0.00014 mol/l
Class : Soluble
Log S (SILICOS-IT) : -4.62
Solubility : 0.00743 mg/ml ; 0.0000241 mol/l
Class : Moderately soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 0.0 alert
Leadlikeness : 0.0
Synthetic accessibility : 2.83

Safety of [ 1092351-67-1 ]

Signal Word:Warning Class:N/A
Precautionary Statements:P261-P305+P351+P338 UN#:N/A
Hazard Statements:H302-H315-H319-H335 Packing Group:N/A
GHS Pictogram:

Application In Synthesis of [ 1092351-67-1 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 1092351-67-1 ]

[ 1092351-67-1 ] Synthesis Path-Downstream   1~6

  • 1
  • [ 1190199-50-8 ]
  • [ 1092351-67-1 ]
YieldReaction ConditionsOperation in experiment
With hydrogenchloride; formic acid; water for 1h; Heating / reflux; Synthesis of 2-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-1H-indole-5-ol (BA24dd); BA24 (3-(4-fluoro-3-methoxyphenyl)-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine, 30 mg, 0.10 mmol) was dissolved in a solution of formic acid (4.5 ml, 10 equivalents) and HCl (0.45 ml, 1 equivalent). The reaction was heated and stirred for one hour under an argon atmosphere. The reaction was then concentrated in vacuo and purified by RP-HPLC (MeCN:H2O:0.1% TFA) to yield BA24dd. ESI-MS (M+H)+ m/z calcd 309.1, found 309.1.
  • 2
  • [ CAS Unavailable ]
  • [ 1092351-67-1 ]
YieldReaction ConditionsOperation in experiment
With hydrogenchloride In 1,4-dioxane; water at 75℃; 1 Compound 2-4 is synthesized as shown in Scheme 2. Compound 1-3 is reacted with isopropyl bromide in dimethylformamide with potassium carbonate at 800C, to provide the 1 -isopropyl pyrazolopyrimidine 2-1. This intermediate with the protected indolyl boronic acid species 2-2, using tetrakistriphenylphosphine palladium catalysis in DME-water solvent at 800C for 4-5 hours, to produce the Suzuki coupling product, compound 2-3. Removal of the protecting groups with acid in dioxane yields the product, 2-( 4-amino-lH-pyrazolo[3,4-d]pyrimidin-3-yl iodide (Cpd. 2-4).
  • 3
  • [ 1203844-07-8 ]
  • [ 1092351-67-1 ]
YieldReaction ConditionsOperation in experiment
With boron tribromide In dichloromethane at -10 - 25℃; 1 An alternative route to perform the Suzuki coupling is shown in Scheme 2-B. In this approach, methyl ether protection is used for the 5-hydroxy on the indolyl boronic acid. Palladium acetate and triphenylphosphine catalyze the coupling in the presence of sodium carbonate base to provide intermediate 2-6. Along with the desired product, some amount of partially de-protected product is also formed. The crude mixture is taken into the next step for complete Boc deprotection reaction with concentrated aqueous HCl in ethanol solution, and compound 2-7 is isolated as the HCl salt. The reaction is brought to approximately pH 8 with aqueous sodium carbonate to obtain the free base. Deprotection with borontribromide affords the final product, 2-( 4-amino-l-isopropyl- lH-pyrazolo[3,4-d]pyrimidin- 3-yl)-lH-indol-5-ol (Compound 2-4). This sequence can be generalized for other compounds of the invention. [
With boron tribromide In dichloromethane at -10 - 25℃; 3B Scheme 3-B. Synthesis of 2-(4-amino-1 -isopropyl- 1H-pyrazolo [3,4- d]pyrimidin-3-yl)- 1H-indol-7-ol (Compound 3-4). The synthesis of 2-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-1H-indol-7-ol (Compound 3-4) is accomplished via the same reactions as in Schemes 1 and 2, using a 7-tert-butyldimethylsilyloxy (TBS) indolyl boronic acid instead of the 5-TBSO indolyl species illustrated. Alternatively, Compound 3-4 is synthesized via methoxy protected intermediates as shown in Scheme 3-B. 5-Methoxy indolyl boronic acid, compound 3-1 is coupled to pyrazolopyrimidine iodide (compound 2-1) using palladium acetate and triphenylphosphine in the presence of sodium carbonate base to provide intermediate 3-6. Along with the desired product, some partially deprotected product is also formed. The crude mixture is taken into the next step for complete Boc deprotection. Deprotection is accomplished with aqueous HCl in ethanol solution and compound 3-7 is isolated as the HCl salt. In the last step, the salt is brought to pH 8 in aqueous potassium carbonate to obtain the free base. This material is treated with boron tribromide to remove the methyl ether protection and yield the final product, Compound 3-4.
  • 4
  • [ 2380-63-4 ]
  • [ 1092351-67-1 ]
YieldReaction ConditionsOperation in experiment
Multi-step reaction with 4 steps 1: N-iodo-succinimide / N,N-dimethyl-formamide / 16 h / 80 °C 2: potassium carbonate / N,N-dimethyl-formamide / 80 °C 3: tetrakis(triphenylphosphine) palladium(0); sodium carbonate / 1,2-dimethoxyethane; water / 80 °C 4: hydrogenchloride / water; 1,4-dioxane / 75 °C
  • 5
  • [ 151266-23-8 ]
  • [ 1092351-67-1 ]
YieldReaction ConditionsOperation in experiment
Multi-step reaction with 3 steps 1: potassium carbonate / N,N-dimethyl-formamide / 80 °C 2: tetrakis(triphenylphosphine) palladium(0); sodium carbonate / 1,2-dimethoxyethane; water / 80 °C 3: hydrogenchloride / water; 1,4-dioxane / 75 °C
  • 6
  • [ 1203844-01-2 ]
  • [ 1092351-67-1 ]
YieldReaction ConditionsOperation in experiment
With hydrogenchloride In 1,4-dioxane; water at 75℃; 41 Scheme 1. Synthesis of 2-(4-amino- 1 H-pyrazolo [3,4-d]pyrimidin-3-yl) iodide (Compound 2-4). Compound 2-4 is synthesized as shown in Scheme 2. Compound 1-3 is reacted with isopropyl bromide in dimethylformamide with potassium carbonate at 80° C., to provide the 1-isopropyl pyrazolopyrimidine intermediate, compound 2-1. This intermediate with the protected indolyl boronic acid species 2-2, using tetrakistriphenylphosphine palladium catalysis in DME-water solvent at 80° C. for 4-5 hours, to produce the Suzuki coupling product, compound 2-3. Removal of the protecting groups with acid in dioxane yields the product, 2-(4-amino-1H-pyrazolo[3,4-d]pyrimidin-3-yl) iodide (Cpd. 2-4).
Same Skeleton Products
Historical Records